DOP2016000136A - Inhibidores de la quinasa reguladora de la señal de apoptosis - Google Patents
Inhibidores de la quinasa reguladora de la señal de apoptosisInfo
- Publication number
- DOP2016000136A DOP2016000136A DO2016000136A DO2016000136A DOP2016000136A DO P2016000136 A DOP2016000136 A DO P2016000136A DO 2016000136 A DO2016000136 A DO 2016000136A DO 2016000136 A DO2016000136 A DO 2016000136A DO P2016000136 A DOP2016000136 A DO P2016000136A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- inhibitors
- ask1
- criminal
- age
- agency
- Prior art date
Links
- 230000006907 apoptotic process Effects 0.000 title abstract 2
- 230000001105 regulatory effect Effects 0.000 title abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 abstract 2
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 abstract 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361918784P | 2013-12-20 | 2013-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2016000136A true DOP2016000136A (es) | 2016-06-30 |
Family
ID=52282961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2016000136A DOP2016000136A (es) | 2013-12-20 | 2016-06-14 | Inhibidores de la quinasa reguladora de la señal de apoptosis |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9908875B2 (enExample) |
| EP (1) | EP3083615B1 (enExample) |
| JP (3) | JP2016540029A (enExample) |
| KR (1) | KR20160098463A (enExample) |
| CN (1) | CN105980382A (enExample) |
| AP (1) | AP2016009248A0 (enExample) |
| AU (1) | AU2014366235B2 (enExample) |
| CA (1) | CA2934454C (enExample) |
| CL (1) | CL2016001538A1 (enExample) |
| CR (1) | CR20160268A (enExample) |
| CU (1) | CU20160095A7 (enExample) |
| DO (1) | DOP2016000136A (enExample) |
| EA (1) | EA201690973A1 (enExample) |
| ES (1) | ES2731703T3 (enExample) |
| HK (1) | HK1226073A1 (enExample) |
| IL (1) | IL245807A0 (enExample) |
| MD (1) | MD4658B1 (enExample) |
| MX (1) | MX2016008254A (enExample) |
| NZ (1) | NZ720660A (enExample) |
| PE (1) | PE20160859A1 (enExample) |
| PH (1) | PH12016501149A1 (enExample) |
| SG (1) | SG11201604473VA (enExample) |
| WO (1) | WO2015095059A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI625121B (zh) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| KR101759759B1 (ko) * | 2010-07-02 | 2017-07-19 | 길리애드 사이언시즈, 인코포레이티드 | 세포자멸사 신호-조절 키나아제 저해제 |
| UY35212A (es) * | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Inhibidores de la quinasa que regula la señal de la apoptosis |
| US9963443B2 (en) * | 2014-06-09 | 2018-05-08 | Takeda Pharmaceutical Company Limited | Radiolabeled compounds |
| WO2018090869A1 (zh) * | 2016-11-16 | 2018-05-24 | 广东东阳光药业有限公司 | 酰胺衍生物及其在药物中的应用 |
| WO2018094964A1 (zh) * | 2016-11-25 | 2018-05-31 | 武汉大学 | 一种以凋亡信号调节激酶1n端二聚化为靶点筛选用于治疗脂肪性肝炎药物的方法 |
| EP3533451B1 (en) | 2017-01-21 | 2022-07-27 | Guangzhou Hanfang Pharmaceuticals Co., Ltd. | Application of paeoniflorin-6'-o-benzene sulfonate in medicine for treating sjögren's syndrome |
| MX376618B (es) * | 2017-01-22 | 2025-03-07 | Fujian Akeylink Biotechnology Co Ltd | Derivado de piridina como inhibidor de ask1 y metodo de preparacion y uso del mismo |
| WO2018157857A1 (zh) * | 2017-03-03 | 2018-09-07 | 江苏豪森药业集团有限公司 | 凋亡信号调节激酶抑制剂及其制备方法和应用 |
| EP3621615B1 (en) | 2017-05-12 | 2023-11-15 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2018218042A1 (en) | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US10246439B2 (en) | 2017-05-25 | 2019-04-02 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US10450301B2 (en) | 2017-05-25 | 2019-10-22 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2019046186A1 (en) | 2017-08-28 | 2019-03-07 | Enanta Pharmaceuticals, Inc. | INHIBITORS OF KINASE 1 REGULATING THE APOPTOTIC SIGNAL CONTAINING TETRAZOLES AND METHODS OF USE THEREOF |
| WO2019072130A1 (zh) * | 2017-10-12 | 2019-04-18 | 深圳市塔吉瑞生物医药有限公司 | 一种1,2,4-三氮唑类化合物 |
| EP3735404B1 (en) | 2018-01-02 | 2023-11-29 | Seal Rock Therapeutics, Inc. | Ask1 inhibitor compounds and uses thereof |
| CN110407806B (zh) * | 2018-04-28 | 2021-08-17 | 深圳微芯生物科技股份有限公司 | 甲酰胺类化合物、其制备方法及其应用 |
| MX2020011225A (es) * | 2018-05-02 | 2021-01-20 | Enanta Pharm Inc | Tetrazol que contiene inhibidores de la cinasa 1 reguladora de la señal de apoptosis y métodos de uso de los mismos. |
| WO2019213239A1 (en) | 2018-05-02 | 2019-11-07 | Enanta Pharmaceuticals Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| ES3032286T3 (en) * | 2018-06-27 | 2025-07-16 | Biogen Ma Inc | Ask1 inhibiting agents |
| US10968199B2 (en) | 2018-08-22 | 2021-04-06 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US11345699B2 (en) | 2018-11-19 | 2022-05-31 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2020198214A1 (en) | 2019-03-25 | 2020-10-01 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101759759B1 (ko) | 2010-07-02 | 2017-07-19 | 길리애드 사이언시즈, 인코포레이티드 | 세포자멸사 신호-조절 키나아제 저해제 |
| UY35212A (es) * | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Inhibidores de la quinasa que regula la señal de la apoptosis |
-
2014
- 2014-12-15 EP EP14824288.6A patent/EP3083615B1/en active Active
- 2014-12-15 MD MD20160069A patent/MD4658B1/ro not_active IP Right Cessation
- 2014-12-15 SG SG11201604473VA patent/SG11201604473VA/en unknown
- 2014-12-15 ES ES14824288T patent/ES2731703T3/es active Active
- 2014-12-15 PE PE2016000806A patent/PE20160859A1/es not_active Application Discontinuation
- 2014-12-15 KR KR1020167019208A patent/KR20160098463A/ko not_active Withdrawn
- 2014-12-15 EA EA201690973A patent/EA201690973A1/ru unknown
- 2014-12-15 CR CR20160268A patent/CR20160268A/es unknown
- 2014-12-15 WO PCT/US2014/070362 patent/WO2015095059A1/en not_active Ceased
- 2014-12-15 JP JP2016540662A patent/JP2016540029A/ja not_active Withdrawn
- 2014-12-15 HK HK16114514.0A patent/HK1226073A1/zh unknown
- 2014-12-15 NZ NZ720660A patent/NZ720660A/en not_active IP Right Cessation
- 2014-12-15 US US15/105,372 patent/US9908875B2/en active Active
- 2014-12-15 US US14/570,655 patent/US9169243B2/en active Active
- 2014-12-15 CA CA2934454A patent/CA2934454C/en not_active Expired - Fee Related
- 2014-12-15 MX MX2016008254A patent/MX2016008254A/es unknown
- 2014-12-15 CN CN201480069141.7A patent/CN105980382A/zh active Pending
- 2014-12-15 AP AP2016009248A patent/AP2016009248A0/en unknown
- 2014-12-15 AU AU2014366235A patent/AU2014366235B2/en not_active Ceased
-
2016
- 2016-05-24 IL IL245807A patent/IL245807A0/en unknown
- 2016-06-14 DO DO2016000136A patent/DOP2016000136A/es unknown
- 2016-06-14 PH PH12016501149A patent/PH12016501149A1/en unknown
- 2016-06-16 CL CL2016001538A patent/CL2016001538A1/es unknown
- 2016-06-20 CU CUP2016000095A patent/CU20160095A7/es unknown
-
2017
- 2017-08-04 JP JP2017151559A patent/JP6509968B2/ja not_active Expired - Fee Related
-
2019
- 2019-01-29 JP JP2019013185A patent/JP2019077719A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2016000136A (es) | Inhibidores de la quinasa reguladora de la señal de apoptosis | |
| MX2015008090A (es) | Compuestos de piridina-2-carboxamida sustituida como inhibidores de cinasa reguladora de señal de apoptosis. | |
| MX389256B (es) | Compuestos heterociclicos y usos de los mismos. | |
| EA201690629A1 (ru) | Соединения, которые представляют собой тройные агонисты, глюкагона, glp-1 и gip | |
| LT3010910T (lt) | Pirimidindiono junginiai, skirti širdies ligoms | |
| UY35233A (es) | Derivados de Exendina-4 como agonistas dobles de GLP1/GIP o triples de GLP1/GIP/Glucagón | |
| JO3357B1 (ar) | مركبات إيميدازوبيروليدينون | |
| DK3230736T3 (da) | Fremgangsmåder til måling af ErbB-signaleringsvejsaktivitet til at diagnosticere og behandle cancerpatienter | |
| MX373307B (es) | Compuestos de biaril-amida como inhibidores de cinasa. | |
| MX2015016303A (es) | Uso de derivados del acido tetramico como nematicidas. | |
| PE20151727A1 (es) | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c | |
| PH12015502649A1 (en) | Heterocyclic compounds as pest control agents | |
| EA201690268A1 (ru) | Замещенные производные хиназолин-4-она | |
| EA201690007A1 (ru) | Соединения, ингибирующие металлоферменты | |
| EA201790599A1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
| EP3128932C0 (en) | CANNULA FOR CONNECTING MEDICAL DEVICES TO BIOLOGICAL SYSTEMS | |
| DK3065818T3 (da) | Anordning til behandling af sygdomme i centralnervesystemet ved hjælp af sansestimulering | |
| MX2016009794A (es) | Derivado de sulfonamida heterociclico y medicina que comprende el mismo. | |
| EP2874626A4 (en) | TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS | |
| EA201790912A1 (ru) | Гетероциклическое соединение | |
| LT2961426T (lt) | Centrinės nervų sistemos susirgimų gydymas, per nosį įvedant imunoglobuliną g | |
| EP2874622A4 (en) | TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS | |
| HUE051295T2 (hu) | Módosított fibroblaszt növekedési faktorok-1 szembetegségek kezelésére | |
| HUE045087T2 (hu) | Eljárás fû vagy széna feldolgozására | |
| MX2019002607A (es) | Composiciones y metodos para el tratamiento de resistencia a la insulina. |